---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-265627"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T18:25:39.500231+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Sarepta enters $500M upfront license deal with Arrowhead for siRNA therapies; GC resigns

## Summary
- $500M upfront cash to Arrowhead; up to $300M near-term payments; up to $180M per program development milestones, $700M per program sales milestones; tiered royalties up to low double digits.
- Sarepta purchases 11.9M shares of Arrowhead for $325M in a private placement, with 180-day lock-up and standstill for up to 5 years.
- Programs include clinical siRNA candidates for FSHD, DM1, ataxias, IPF, and pre-clinical for Huntington's; Sarepta can select six additional discovery targets.
- Arrowhead leads initial development and manufacturing; Sarepta assumes responsibility at transition points and holds global commercialization rights.
- EVP Chief General Counsel Ryan Brown resigns effective Nov 26; Cristin Rothfuss named successor as EVP General Counsel.

## SEC filing metadata
- accession: 0001193125-24-265627
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/0001193125-24-265627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/d856104d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-265627
- JSON: https://secwatch.observer/filing/0001193125-24-265627.json
- Plain text: https://secwatch.observer/filing/0001193125-24-265627.txt

## Key facts
- Executive change
  Ryan Brown resigned as Executive Vice President, Chief General Counsel at Sarepta Therapeutics, Inc..
  - Action: resigned
  - Role: Executive Vice President, Chief General Counsel
  source text: Ryan Brown informed Sarepta of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/0001193125-24-265627-index.htm
- Executive change
  Cristin Rothfuss was appointed as Executive Vice President, General Counsel at Sarepta Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Vice President, General Counsel
  source text: Cristin Rothfuss, the Company’s Senior Vice President, Deputy General Counsel, will succeed Mr. Brown as the Company’s Executive Vice President, General Counsel.
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312524265627/0001193125-24-265627-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.